Physician profile
Ryan Hanson
NPI 1891769006
$6,152.83
in general payments reported to CMS, 2019-2025
22 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $373 · 2022: $871 · 2023: $1,805 · 2024: $1,590 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,898 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,898.35 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,508.49 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,528.68 | 2022-2025 | Descovy, Yeztugo |
| Lilly USA, LLC | $357.90 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Napo Pharmaceuticals INC | $312.32 | 2023-2025 | Mytesi |
| Theratechnologies INC. | $211.54 | 2023-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Janssen Biotech, INC. | $199.76 | 2022-2023 | Symtuza |
| Abbvie INC. | $199.64 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $147.94 | 2022-2023 | Delstrigo, Pifeltro, Dificid |
| Antares Pharma, INC. | $91.31 | 2024-2025 | Xyosted |
| Novo Nordisk INC | $80.58 | 2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.49 | 2023-2024 | Xifaxan |
| Organon LLC | $78.25 | 2022 | |
| Verity Pharmaceuticals INC. | $65.01 | 2025 | Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.83 | 2023 | Synjardy, Spiriva Respimat, Tradjenta |
| Exact Sciences Corporation | $55.05 | 2024-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $32.86 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Corium, LLC | $32.69 | 2024 | Azstarys |
| Janssen Products, Lp | $29.99 | 2021 | |
| Emd Serono, INC. | $25.75 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.46 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $22.79 | 2025 | Shingrix |
| Axsome Therapeutics, INC. | $9.50 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.